Patents by Inventor Karuppiah Muthumani

Karuppiah Muthumani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190091322
    Abstract: Disclosed herein is a composition comprising the combination of a nucleic acid sequence encoding a desired polypeptide that elicits an immune response in a mammal and a nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof.
    Type: Application
    Filed: March 21, 2017
    Publication date: March 28, 2019
    Inventors: David B. Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai, Sarah Elliott, Jian Yan, Ami Patel
  • Publication number: 20190085058
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
    Type: Application
    Filed: September 26, 2018
    Publication date: March 21, 2019
    Inventors: David Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai
  • Patent number: 10226528
    Abstract: Disclosed herein is a vaccine comprising an antigen and one or more bimolecular adjuvant. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 12, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Karuppiah Muthumani
  • Publication number: 20190022213
    Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
    Type: Application
    Filed: June 29, 2018
    Publication date: January 24, 2019
    Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
  • Patent number: 10155795
    Abstract: Disclosed herein is a therapeutic comprising hypoxia inducible factor-1 alpha (HIF-1?). Also disclosed herein is a method for treating hypoxia or ischemia in a subject in need thereof. The method may comprise administering the vaccine to the subject in need thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 18, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Karuppiah Muthumani, Emile Mohler, Geoffrey Ouma
  • Patent number: 10087240
    Abstract: The present invention relates to a composition including a recombinant nucleic acid sequence that encodes an antibody and a method of generating a synthetic antibody in a subject by administering the composition to the subject. The invention also provides a method of preventing and/or treating disease in a subject using the composition and method of generation.
    Type: Grant
    Filed: December 13, 2014
    Date of Patent: October 2, 2018
    Assignee: INOVIO PHARMACEUTICALS, INC.
    Inventors: David Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai
  • Patent number: 10040828
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an RSV immunogen are disclosed. Nucleic acid are disclosed that comprise the sequences that encodes consensus RSV F protein or immunogenic fragment thereof, sequences that encodes an RSV G(A) protein or immunogenic fragment thereof and sequences that encodes an RSV G(B) protein or immunogenic fragment thereof. Compositions comprising one, combinations of two or all three sequences are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Nucleic acid molecules and compositions comprising the chemokine CC20 and/or a consensus RSV M2-1 protein or immunogenic fragment thereof are also disclosed. Immunomodulatory methods and methods of inducing an immune response against RSV are disclosed. Method of preventing RSV infection and methods of treating individuals infected with RSV are disclosed.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: August 7, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Daniel Choo, Karuppiah Muthumani, Nyamekye Obeng-Adjei, Veronica Scott
  • Patent number: 10016497
    Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: July 10, 2018
    Assignees: THE TRUSTEES OF THE UNIVERSTIY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
  • Patent number: 9994629
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: June 12, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Karuppiah Muthumani, Niranjan Sardesai, Seleeke Flingai
  • Patent number: 9993545
    Abstract: The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 12, 2018
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David B. Weiner, Jian Yan, Karuppiah Muthumani, Niranjan Y. Sardesai
  • Publication number: 20180015161
    Abstract: Disclosed herein is a vaccine comprising an antigen and checkpoint inhibitor. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.
    Type: Application
    Filed: January 28, 2016
    Publication date: January 18, 2018
    Inventors: David Weiner, Karuppiah Muthumani, Niranjan Sardesai
  • Publication number: 20180000928
    Abstract: Provided herein is a vaccine comprising a Porcine Epidemic Diarrhea Virus (PEDV) antigen. The antigen can be a consensus antigen. Also disclosed herein is a method of treating a porcine in need thereof, by administering the vaccine to the porcine.
    Type: Application
    Filed: January 22, 2016
    Publication date: January 4, 2018
    Inventors: David Weiner, Emma L. Reuschel, Karuppiah Muthumani
  • Publication number: 20170266282
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
    Type: Application
    Filed: December 1, 2015
    Publication date: September 21, 2017
    Applicants: Inovio Pharmaceuticals, Inc., The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai
  • Publication number: 20170258893
    Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
    Type: Application
    Filed: November 26, 2014
    Publication date: September 14, 2017
    Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
  • Publication number: 20160256539
    Abstract: The present invention is directed to an effective HIV vaccine will most likely require the induction of strong T-cell responses, broadly neutralizing antibodies (bNAbs), and the elicitation of antibody-dependent cellular cytotoxicity (ADCC). Previously, we demonstrated the induction of strong HIV/SIV cellular immune responses in macaques and humans using synthetic consensus DNA immunogens delivered via adaptive electroporation (EP). However, the ability of this improved DNA approach to prime for relevant antibody responses has not been previously studied. Here, we investigate the immunogenicity of consensus DNA constructs encoding gp140 sequences from HIV-1 subtypes A, B, C and D in a DNA prime protein boost vaccine regimen. Mice and Guinea pigs were primed with single and multi-clade DNA via EP and boosted with recombinant gp120 protein. Sera were analyzed for gp120 binding and induction of neutralizing antibody activity.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 8, 2016
    Inventors: David Weiner, Karuppiah Muthumani, Megan Wise, Jian Yan, Kate Broderick
  • Publication number: 20160067334
    Abstract: Disclosed herein is a vaccine comprising an antigen and one or more bimolecular adjuvant. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: March 10, 2016
    Inventors: David WEINER, Karuppiah MUTHUMANI
  • Publication number: 20160045589
    Abstract: The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 18, 2016
    Inventors: David WEINER, Jian YAN, Karuppiah MUTHUMANI, Niranjan Y. SARDESAI
  • Publication number: 20160039886
    Abstract: Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.
    Type: Application
    Filed: August 3, 2015
    Publication date: February 11, 2016
    Inventors: David B. Weiner, Bernadette Ferraro, Jian Yan, Patricia A. Brown, Rodney A. Bowling, Douglas R. Kern, Mathura P. Ramanathan, Niranjan Y. Sardesai, Karuppiah Muthumani
  • Publication number: 20160030536
    Abstract: Disclosed herein are compositions and methods for treating cancer and in particular vaccines that treat and provide protection against tumor growth.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: David WEINER, Karuppiah MUTHUMANI, Jewell WALTERS, Jian YAN
  • Publication number: 20150284448
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
    Type: Application
    Filed: December 13, 2013
    Publication date: October 8, 2015
    Applicant: Inovio Pharmaceuticals, Inc.
    Inventors: David B. Weiner, Karuppiah Muthumani, Niranjan Sardesai, Seleeke Flingai